Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
Thirty six APML patients achieving hematological remission with As2O3 were serially monitored using RT-PCR. Though only 5.5% achieved molecular remission at induction remission, 94.5% became negative during consolidation. At 20 months follow-up, 85% remain in remission but longer follow up studies are needed to monitor late relapses.
Biju
B
George
Likram
L
Mathews
Poonkuzhali
P
Balasubramanian
R V
RV
Shaji
Alok
A
Srivastava
Mammen
M
Chandy
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000097:blood / Q000235:genetics; D010087:Oxides / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D051562:Proto-Oncogene Proteins c-bcr / Q000097:blood / Q000235:genetics; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr; D000077237:Arsenic Trioxide